Novo Nordisk AS will price the first oral glucagon-like peptide-1 agonist Rybelsus (semaglutide) in the US at a similar list price to the injectable version, marketed by Novo as Ozempic since 2017. However, Novo may have to offer significant discounts to gain traction with payers.
Both the 7mg and 14mg doses of the new once-daily oral pill will launch at a wholesale acquisition cost (WAC)...






